Form 4: Alnylam Pharmaceuticals CEO Yvonne Greenstreet Reports Stock Transactions

Alnylam Pharmaceuticals CEO Yvonne Greenstreet reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, reported transactions involving Alnylam common stock.
• On February 27, 2024, 5,921 restricted stock units vested, converting into common stock.
• Simultaneously, 5,921 shares were acquired at $0.00 per share due to the vesting of these restricted stock units.
• To cover statutory tax withholding obligations, Greenstreet sold shares on February 28, 2024.
• The sales occurred in multiple transactions at weighted average prices ranging from $154.54 to $158.09.
• Greenstreet also holds 407 shares indirectly through a managed account and additional shares through the issuer's 401(k) plan.
• Following these transactions, Greenstreet directly owns 48,128 shares of Alnylam common stock.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions, with no inherent positive or negative implications for the company's performance.

Industry Context

This is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry.

Comparison to Industry Standards

• Executive stock transactions are a normal part of compensation packages in publicly traded companies, including pharmaceutical firms like Alnylam.
• Similar transactions are regularly reported by executives at companies like Moderna, BioNTech, and Vertex Pharmaceuticals.
• The sale of shares to cover tax obligations upon vesting of restricted stock units is a standard practice.

Stakeholder Impact

• The transactions have a minimal direct impact on shareholders, employees, customers, suppliers, and creditors.
• The sale of shares by the CEO could slightly increase the stock's trading volume.

Key Dates